内部问责制度 （2025 年修订） 第一章 总则 第一条 为了进一步完善北京北陆药业股份有限公司（以下简称"公司"）法人治理结 构，健全内部约束和责任追究机制，促进公司董事、高级管理人员恪尽职守、勤勉尽责， 提高公司决策与经营管理水平，建设廉洁、务实、高效的管理团队，根据《中华人民共和 国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《深圳证券交易所创业板股票上市规则》（以下简称"《创业板上市规则》"）、《深圳证券交 易所上市公司自律监管指引第 2 号－－创业板上市公司规范运作》（以下简称"《创业板规 范运作指引》"）等法律、行政法规、规范性文件及公司内部控制制度等相关规定，特制定 本制度。 第二条 公司董事高级管理人员须自觉遵守《公司法》、《证券法》、《创业板上市规则》、 《创业板规范运作指引》等相关法律、法规、规范性文件及《公司章程》（以下简称"《公 司章程》"）等公司内控体系制度，规范履行职责的行为。 第三条 内部问责制是指对公司董事高级管理人员在其所管辖的部门及工作职责范围 内，因其故意、过失、不作为、不履行或者不正确履行工作职责给公司造成不良影响和后 果的 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 北京北陆药业股份有限公司《2025 年第三季度报告》已于 2025 年 10 月 29 日在中国证监会指定的创业板信息披露网站上披露，请投资者注意查阅。 特此公告。 股票代码：300016 股票简称：北陆药业 公告编号：2025-109 北京北陆药业股份有限公司 2025年第三季度报告披露提示性公告 北京北陆药业股份有限公司 董事会 二○二五年十月二十九日 1 ...

股票代码：300016 股票简称：北陆药业 公告编号：2025-111 北京北陆药业股份有限公司 1 关于为全资子公司陆芝葆药业有限公司提供担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、担保情况概述 为保障北京北陆药业股份有限公司（以下简称"公司"或"北陆药业"） 全资子公司陆芝葆药业有限公司（以下简称"陆芝葆药业"）"中药提取、中成 药、高端化药制剂生产项目"建设的资金需求，公司于 2025 年 10 月 27 日召 开第九届董事会第五次会议，审议并通过《关于为全资子公司陆芝葆药业有限 公司提供担保的议案》。董事会同意公司为全资子公司陆芝葆药业提供不超过 4 亿元人民币的连带责任保证担保，担保期限不超过十年。 根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司 自律监管指引第 2 号——创业板上市公司规范运作》等法律法规、规范性文件 及《公司章程》的规定，公司为陆芝葆药业提供担保金额超过公司最近一期经 审计净资产 10%，此次担保事项需提交公司股东会审议。 二、被担保人基本情况 被担保人系公司全资子公司陆芝葆药业，其基本情况如 ...

股票代码：300016 股票简称：北陆药业 公告编号：2025-112 1、股东会届次：2025年第四次临时股东会 北京北陆药业股份有限公司 关于召开2025年第四次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、召开会议的基本情况 4、会议时间： 2、股东会的召集人：董事会 （1）现场会议时间：2025年11月13日14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间 为2025年11月13日9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所 互联网投票系统投票的具体时间为2025年11月13日9:15至15:00的任意时间。 5、会议的召开方式：本次会议采取现场投票和网络投票相结合的方式 （1）现场投票：包括本人出席及通过填写授权委托书授权他人出席。 （2）网络投票：公司将通过深圳证券交易所交易系统和互联网投票系统 （wltp.cninfo.com.cn）向全体股东提供网络形式的投票平台，股东可以在网 1 络投票时间内通过上述系统行使表决权。公司股东应选择现场投票、网络投 票中 ...

北京北陆药业股份有限公司 股票代码：300016 股票简称：北陆药业 公告编号：2025-113 第九届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 北京北陆药业股份有限公司（以下简称"公司"）第九届董事会第五次 会议于2025年10月27日下午以现场及通讯相结合的方式召开，会议通知以邮 件方式送达各位董事。本次会议应出席董事9人，实际出席董事9人，实际参 加表决董事9人。本次会议的召集召开程序符合《公司法》和《公司章程》的 有关规定。会议由董事长王旭先生主持，与会董事以记名投票方式审议通过 了以下议案： 一、《2025年第三季度报告》 董事会审议通过《2025 年第三季度报告》。 具体内容详见公司于巨潮资讯网（www.cninfo.com.cn）等中国证监会指定 信息披露网站披露的《2025 年第三季度报告》，《2025 年第三季度报告披露提 示性公告》同时刊登在公司指定信息披露报刊：《中国证券报》、《证券时报》 及《上海证券报》。 本报告已经公司第九届董事会审计委员会第四次会议审议通过。 本议案尚需提交2025年第四次临时股东 ...

Financial Performance - The company's revenue for Q3 2025 reached ¥288,476,088.66, representing a year-on-year increase of 12.78%[4] - Net profit attributable to shareholders for Q3 2025 was ¥14,209,974.14, a significant increase of 192.80% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥3,938,214.59, down 35.49% year-on-year[4] - Total operating revenue for the current period reached ¥872,684,962.37, an increase of 19.5% compared to ¥729,717,058.01 in the previous period[27] - Net profit for the current period was ¥39,465,985.79, representing a 107.5% increase from ¥19,003,632.36 in the previous period[28] - Operating profit increased to ¥45,817,686.82, compared to ¥22,903,585.39 in the last period, reflecting a growth of 100.1%[27] - Basic earnings per share improved to ¥0.0870 from ¥0.0497, reflecting a 74.5% increase[28] Assets and Liabilities - Total assets at the end of Q3 2025 amounted to ¥3,221,782,955.47, reflecting an 8.20% increase from the end of the previous year[6] - The company's total assets rose to ¥3,221,782,955.47, up from ¥2,977,531,229.66, marking an 8.2% increase[25] - Total liabilities decreased to ¥852,799,245.56 from ¥1,148,042,995.20, a reduction of 25.7%[25] - Shareholders' equity attributable to the company reached ¥2,211,059,191.73, up 32.59% from the end of the previous year[6] - The equity attributable to shareholders of the parent company increased to ¥2,211,059,191.73, compared to ¥1,667,588,937.34, a growth of 32.6%[25] Cash Flow - Cash flow from operating activities for the year-to-date was ¥129,222,252.74, a decrease of 6.06% compared to the previous year[4] - The company reported a significant increase in cash flow from operating activities, contributing to improved liquidity and financial stability[29] - Cash inflow from operating activities totaled $926.44 million, an increase of 7.1% from $864.98 million in the previous period[30] - The net cash flow from operating activities was $129.22 million, a decrease of 6.5% from $137.57 million in the previous period[30] - Total cash and cash equivalents at the end of the period reached $305.93 million, up from $244.77 million in the previous period[32] Investments and Financing - The company reported a net cash outflow from investing activities of ¥140,143,400, a decrease of 77.60% year-on-year[11] - Net cash outflow from investment activities was $140.14 million, an improvement from a net outflow of $625.66 million in the previous period[32] - Cash paid for the purchase of fixed assets and intangible assets was $168.50 million, significantly higher than $74.53 million in the previous period[31] - Cash inflow from financing activities was $309.70 million, compared to $148.37 million in the previous period, marking a significant increase[32] Research and Development - R&D expenses for the period were ¥24,935,800, representing a 40.72% increase year-on-year, impacting net profit attributable to shareholders[10] - Research and development expenses for the current period were ¥63,963,081.76, up from ¥53,171,942.94, indicating a 20.3% increase[27] Market and Regulatory Developments - The company received market access qualifications for iodine contrast agents in South Korea and India in March and July 2025, respectively[19] - The company obtained GMP certification from Brazil's National Health Surveillance Agency in September 2025[19] Shareholder Information - The total number of restricted shares at the end of the period was 758,475, down from 772,075 at the beginning of the period[18] - The company plans to issue shares to specific targets through a simplified procedure in 2025[19]

Policy Developments - The National Health Commission emphasizes the construction of a fertility-friendly society, promoting supportive policies for childbirth, elderly care, and the gradual delay of retirement age to optimize population structure [1] Drug Approval - East China Pharmaceutical's subsidiary received approval for the drug Mevanertinib, a new treatment for advanced or metastatic non-small cell lung cancer, with a direct R&D investment of approximately 306 million yuan [2] - Hengrui Medicine's subsidiary received approval for a fixed-dose combination of three oral diabetes medications, marking the first of its kind in China [3] Financial Reports - Shuanglu Pharmaceutical reported a 143.28% year-on-year increase in net profit for Q3, driven by gains from financial assets [4] - Huitai Medical announced a 18.02% increase in net profit for the first three quarters, with Q3 revenue up 24.77% [5] Capital Market - WuXi AppTec plans to sell 100% equity of two subsidiaries for 2.8 billion yuan to focus on its CRDMO business model, enhancing its global capabilities [7] Industry Events - The Ministry of Industry and Information Technology conducted a survey on the traditional Chinese medicine industry, aiming to promote modernization and quality improvement [8] - Shanghai's biopharmaceutical industry is projected to exceed 1 trillion yuan, marking it as the fifth trillion-level industry in the city [9] - The Jiangxi Pharmaceutical Development Conference resulted in the signing of 16 key pharmaceutical projects across various sectors [10] Public Sentiment - Beilu Pharmaceutical announced that a major shareholder plans to reduce its stake by up to 1.78% to improve asset liquidity [11]

Core Insights - On October 24, seven A-share listed companies disclosed share reduction plans, with no companies announcing share increases on the same day [1]. Summary by Company - **Beilu Pharmaceutical**: Shareholder Sanxia Paint plans to reduce its stake by no more than 1.78% [2]. - **Abison**: Controlling shareholder Ding Yanhui intends to reduce his stake by no more than 3% [2]. - **Zhongke Feice**: Shareholder Guotou Chuangye Fund plans to reduce its stake by no more than 3% [2]. - **Liyang Chip**: Controlling shareholder and actual controller Huang Jiang plans to reduce his stake by no more than 600,000 shares [2]. - **Qifan Cable**: Controlling shareholder and actual controllers plan to collectively reduce their stake by no more than 3.5% [2]. - **Shangtai Technology**: Shareholder Changjiang Changdao plans to reduce his stake by no more than 2% [2]. - **Huayang Group**: Shareholders Zhongshan Zhongke and Zhongke Baiyun plan to collectively reduce their stake by no more than 1.5% [2].

Core Viewpoint - On October 24, seven A-share listed companies disclosed share reduction plans, with no companies announcing share increases on the same day [1]. Group 1: Company Share Reduction Details - Beilu Pharmaceutical: Shareholder Sanxia Paint plans to reduce its stake by no more than 1.78% [2]. - Aibisen: Controlling shareholder Ding Yanhui intends to reduce his stake by no more than 3% [2]. - Zhongke Feicai: Shareholder Guotou Chuangye Fund plans to reduce its stake by no more than 3% [2]. - Liyang Chip: Controlling shareholder and actual controller Huang Jiang plans to reduce his stake by no more than 600,000 shares [2]. - Qifan Cable: Controlling shareholder and actual controllers plan to collectively reduce their stake by no more than 3.5% [2]. - Shangtai Technology: Shareholder Changjiang Changdao plans to reduce its stake by no more than 2% [2]. - Huayang Group: Shareholders Zhongshan Zhongke and Zhongke Baiyun plan to collectively reduce their stake by no more than 1.5% [2]. Group 2: Market Signals - The formation of a MACD golden cross signal indicates a positive trend for these stocks [2].

Performance Disclosure - Chifeng Jilong Gold reported a 140.98% year-on-year increase in net profit attributable to shareholders in Q3, with revenue of 3.372 billion yuan, up 66.39% [1] - Guoxuan High-Tech achieved a staggering 1434.42% increase in net profit attributable to shareholders in Q3, with revenue of 10.114 billion yuan, up 20.68% [2] - Sichuan Changhong saw a 690.83% increase in net profit attributable to shareholders in Q3, despite a 2.69% decline in revenue to 25.184 billion yuan [3] - CITIC Securities reported a 51.54% increase in net profit attributable to shareholders in Q3, with revenue of 22.775 billion yuan, up 55.71% [4] Shareholding Changes - Beilu Pharmaceutical announced that its shareholder, Chongqing Three Gorges Paint Co., plans to reduce its stake by up to 1.78%, equivalent to no more than 10 million shares [5] - Zhejiang Liming disclosed that its shareholder, Yifan Investment, reduced its stake by 2.84%, totaling approximately 4.17 million shares [6] - Diou Waterhua revealed plans for shareholder Wang Zhihong to increase his stake by 100 million to 200 million yuan within six months [7] Risk Matters - Aowei New Materials indicated a potential application for stock suspension due to significant price deviations from its fundamental situation [8] - Wentai Technology warned of potential risks for revenue, profit, and cash flow adjustments if control issues are not resolved by the end of 2025 [9][10] - ST Chuangyi faced a fine of 4 million yuan for violations related to information disclosure, affecting several key executives with individual fines [11]